Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Khong HT, Restifo NP.

Nat Immunol. 2002 Nov;3(11):999-1005. Review.

2.

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S.

Adv Immunol. 2000;74:181-273. Review. No abstract available.

PMID:
10605607
3.

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F.

Cancer Immunol Immunother. 2004 Oct;53(10):904-10. Epub 2004 Apr 7. Review.

PMID:
15069585
4.

MHC class I antigens, immune surveillance, and tumor immune escape.

Garcia-Lora A, Algarra I, Garrido F.

J Cell Physiol. 2003 Jun;195(3):346-55. Review.

PMID:
12704644
5.

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

Ahmad M, Rees RC, Ali SA.

Cancer Immunol Immunother. 2004 Oct;53(10):844-54. Epub 2004 Jun 10. Review.

PMID:
15197495
6.

Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?

Salih HR, Nüssler V.

Eur J Med Res. 2001 Aug 27;6(8):323-32. Review.

PMID:
11549514
7.

[Antitumor immunity and cellular cancer therapies].

Catros-Quemener V, Bouet F, Genetet N.

Med Sci (Paris). 2003 Jan;19(1):43-53. Review. French.

8.

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.

Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr.

J Immunol. 2005 Jun 1;174(11):6863-71.

9.

Immune selective pressure and HLA class I antigen defects in malignant lesions.

Chang CC, Ferrone S.

Cancer Immunol Immunother. 2007 Feb;56(2):227-36. Epub 2006 Jun 17. Review.

PMID:
16783578
10.
11.

[Immune system and tumors].

Terme M, Tanchot C.

Ann Pathol. 2017 Feb;37(1):11-17. doi: 10.1016/j.annpat.2016.12.004. Epub 2017 Jan 31. Review. French.

PMID:
28159405
12.

Mechanism of immune escape of cancer and its regulation.

Morita R, Hirohashi Y, Torigoe T.

Rinsho Ketsueki. 2009 May;50(5):375-80. Review. No abstract available.

PMID:
19483397
13.

Tumor microenvironment and immune escape.

Ferrone S, Whiteside TL.

Surg Oncol Clin N Am. 2007 Oct;16(4):755-74, viii. Review.

PMID:
18022543
14.

Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Bai XF, Liu J, Li O, Zheng P, Liu Y.

J Clin Invest. 2003 May;111(10):1487-96.

15.

Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.

Campoli M, Ferrone S.

Tissue Antigens. 2008 Oct;72(4):321-34. doi: 10.1111/j.1399-0039.2008.01106.x. Epub 2008 Aug 12. Review.

16.

Natural killer cell immune escape in acute myeloid leukemia.

Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL.

Leukemia. 2012 Sep;26(9):2019-26. doi: 10.1038/leu.2012.87. Epub 2012 Mar 26. Review.

PMID:
22446501
17.

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA.

J Immunol. 1999 Jul 1;163(1):184-93.

18.

Natural killer group 2D receptor and its ligands in cancer immune escape.

Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, Wang Y, Xiong F, Guo C, Li Y, Li X, Li G, Zeng Z, Xiong W, Wang F.

Mol Cancer. 2019 Feb 27;18(1):29. doi: 10.1186/s12943-019-0956-8. Review.

20.

MHC class I antigens and immune surveillance in transformed cells.

Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F.

Int Rev Cytol. 2007;256:139-89. Review.

PMID:
17241907

Supplemental Content

Support Center